Efficacy and Safety of Ibuprofen for Premature Infants with Patent Ductus Arteriosus: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 GUOMing ¹ ^# ,  WANGYa-nan ² ^# , XUJia-ke ³ , QINQian ³ , CHENKuang-yang ³ , SUXu ³ , FUWen-kang ³ , YANGJia-hui ³ ,  LIUDong-hai ¹

1. Department of Neonatology, Gansu Provincial Maternity and Child-care Hospital, Lanzhou 730000, China;
2. The Second Clinical Medical College of Lanzhou University, Lanzhou 73000, China;
3. The First Clinical Medical College of Lanzhou University, Lanzhou 73000, China;

Corresponding?author：

LIUDong-hai, Email: anlanming-2009@163.com

Keywords：

Ibuprofen; Patent ductus arteriosus; Premature infants; Systematic review; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.20160065

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of ibuprofen for premature infants with patent ductus arteriosus. Methods Databases including PubMed, Ovid-EMbase, The Cochrane Library (Issue 11, 2014), CNKI, WanFang Data and VIP were searched to collect randomized controlled trials (RCTs) and quasi-RCTs about ibuprofen for premature infants with patent ductus arteriosus from inception to December 2014. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then meta-analysis was conducted by RevMan 5.3 software. Results A total of 37 RCTs, involving 2 370 patients were included. The results of meta-analysis showed that, compared with the placebo/blank group, ibuprofen could increase the closure rate of PDA (LBWI:RR=1.93, 95%CI 1.25 to 2.99，P=0.003; VLBW:RR=1.23, 95%CI 1.02 to 1.48, P=0.03; ELBWI:RR=2.86, 95%CI 1.51 to 5.41, P=0.001) and decrease the incidence of sepsis (VLBW:RR=0.21, 95%CI 0.07 to 0.64，P=0.006); Compared with the indometacin groups, ibuprofen could decrease the incidence of the increase of serum creatinine (LBWI:RR=0.11, 95%CI 0.04 to 0.37, P=0.000 2), NEC (LBWI, RR=0.52, 95%CI 0.29 to 0.95, P=0.03) and oliguria (LBWI: RR=0.30, 95%CI 0.16 to 0.56, P=0.000 2; VLBW:RR=1.40, 95%CI 1.03 to 1.92, P=0.03); Compared with the intravenous ibuprofen, Oral ibuprofen could increase the closure rate of PDA (VLBW: RR=1.35, 95%CI 1.12 to 1.62, P=0.002; ELBWI, RR=1.42, 95%CI 1.07 to 1.87, P=0.01). Conclusion Current evidence shows that there is not indeterminate between ibuprofen and paracetamol groups. Compared with other general drugs, ibuprofen has an advantage over curing PDA and obviously reduces side effects. Due to the limited quality and quantity of included studies, more high quality studies are needed to verify the above conclusion.

Citation： GUOMing, WANGYa-nan, XUJia-ke, QINQian, CHENKuang-yang, SUXu, FUWen-kang, YANGJia-hui, LIUDong-hai. Efficacy and Safety of Ibuprofen for Premature Infants with Patent Ductus Arteriosus: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2016, 16(4): 415-426. doi: 10.7507/1672-2531.20160065 Copy

1.	Fanos V, Pusceddu M, Dess?` A, Marcialis MA. Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns? Clinics, 2011, 66(12):2141-2149.
2.	Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics, 2010, 125(5):1020-1030.
3.	Sekar KC. Protective strategies to prevent patent ductus arteriosus. Chin Med J(Eng), 2010, 123(20):2914-2918.
4.	Friedman WF, Hirschklau MJ, Printz MP, et al. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med, 1975, 295(10):526-529.
5.	Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Eng J Med, 1976, 295(10):530-533.
6.	Overmeirea BV, Chemtob S. The pharmacologic closure of the patent ductus arteriosus. Seminars infetal Neonata Medicine, 2005, 10(2):177-184.
7.	Itabashi K, Ohno T, Nishida H. Indomethacin responsiveness of patentnducus arteriosus and renal abnormalities in preterm infants treated with indomethacin. J Pediatr, 2003, 143(2):203-207.
8.	Shaffer CL, Gal P, Ronsom JL, et al. Effect of age birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med, 2002, 30(2):343-348.
9.	Hammerman C, Binnun A, Markovitch E, et al. Ductal closure with paracrtamol:A surprising new approach to patent ductus arteriosus treatment. Pediatrics, 2011, 128:e1618-e162.
10.	Overmerre BV, Follens I, Hartmann S, et al. Treatment of patent ductus arteriosus with ibprofen. Arch Dis Child, 1997, 76(3):179-184.
11.	張聰聰, 程國強. 早產兒動脈導管未閉治療的進展. 中華兒科雜志, 2012, 50(11):871-873.
12.	Higgins JPT, Altman DG, Sterne JAC, et al. Chapter 8:Assessing risk of bias in included studies//Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011[OL]. Available at:www.cochrane-handbook.org.
13.	Gokmen T, Erdeve O, Altug N, et al. Efficacy and Safety of Oral Versus Intravenous Ibuprofen in Very Low Birth Weight Preterm Infants with Patent Ductus Arteriosus. The Gournal Of Pediatrics, 2011, 158:549-554.
14.	Pistull E, Qosja A H, Shtiza D, et al. Renal effects of ibuprofen during the treatment of patent ductus arteriosus in low birth weight premature infants. Open Science Journal of Clinical Medicine, 2014, 2(6):123-128.
15.	Cherif A, Khrouf N, Jabnoun S, et al. Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus. Pediatrics, 2008, 122:1256-1261.
16.	Erdeve O, Yurttutan S, Altug N, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure:a randomised controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed, 2012, 97(4):279-283.
17.	Jacob V. Aranda, Ronald Clyman, Blair Cox, et al. A Randomized, Double-Blind, Placebo-Controlled Trial on Intravenous Ibuprofen L-Lysine for the Early Closure of Nonsymptomatic Patent Ductus Arteriosus within 72 Hours of Birth in Extremely Low-Birth-Weight Infants. Am J Perinatol, 2009, 26(3):235-245.
18.	Sangtawesin C, Sangtawesin V, Lertsutthiwong W, et al. Prophylaxis of Symptomatic Patent Ductus Arteriosuswith Oral Ibuprofen in Very Low Birth Weight Infants. J Med Assoc Thai, 2008, 91 (Suppl 3):S28-34.
19.	Sangtawesin V, Sangtawesin C, Raksasinborisut C, et al. Oral Ibuprofen Prophylaxis for Symptomatic Patent Ductus Arteriosus of Prematurity. J Med Assoc Thai, 2006, 89(3):314-321.
20.	黨丹. 對乙酰氨基酚與布洛芬治療早產兒PDA的隨機對照試驗. 長春:吉林大學. 2013.
21.	Oncel MY, Yurttutan S, Erdeve O, et al. Oral Paracetamol versus Oral Ibuprofen in the Management of Patent Ductus Arteriosus in Preterm Infants. J Pediatr, 2014, 164(3):510-514.
22.	龔長富, 葉慧寧, 馮立文. 口服美林對早產兒動脈導管未閉的療效觀察. 小兒急救醫學, 2004, 11(5):317-319.
23.	何莉, 王潔婷, 陸長東, 等. 口服布洛芬和消炎痛關閉早產兒動脈導管未閉的療效和安全性的比較. 中國婦幼保健, 2005, 20(6):752-754.
24.	姜紅, 吳莉華, 葛覺敏. 口服布洛芬治療早產兒動脈導管未閉的療效及安全性. 中國醫學創新, 2009, 6(23):109-110.
25.	雷立容, 丘惠嫻. 布洛芬治療極低出生體重早產兒動脈導管未閉的療效觀察. 海南醫學. 2013, 24(2):202-204.
26.	宋萃春, 張軍. 布洛芬對關閉早產兒動脈導管療效分析. 中外健康文摘, 2014, (14):167-167.
27.	楊春, 張春秀, 徐桂林. 口服布洛芬混懸劑治療早產兒動脈導管未閉的療效觀察, 2006, 22(15):1811-1812.
28.	張磊, 唐建平. 布洛芬混懸液治療新生兒動脈導管未閉的臨床療效分析. 現代診斷與治療, 2013, 24(9):2014-2015.
29.	Fakhraee S H, Badiee Z, MojtahedzadehS, et al. Comparison of oral ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Zhongguo Dang Dai Er Ke Za Zhi, 2007, 9(5):399-403.
30.	Hammerman C, Shchors I, Jacobson S, et al. Ibuprofen Versus Continuous Indomethacin in Premature Neonates With Patent Ductus Arteriosus:Is the Difference in the Mode of Administration? Pediatr Res, 2008, 64(3):291-298.
31.	Yadav S, AgarwalS, Maria A, et al. Comparison of Oral Ibuprofen with Oral Indomethacin for PDA Closure in Indian Preterm Neonates:A Randomized Controlled Trial. Pediatr Cardiol, 2014, 35(5):824-830.
32.	Aly H, Lotfy W, Badrawi N, et al. Oral Ibuprofen and Ductus Arteriosus in Premature Infants:A Randomized Pilot Study. Am J Perinatol, 2007, 24(5):267-270.
33.	Adamska E, Helwich E, Rutkowska M, et al. Comparison of the efficacy of ibuprofen and indomethacin in the treatment of patent ductus arteriosus in prematurely born infants. Med Wieku Rozwoj, 2005, 9(3 Pt 1):335-354.
34.	Akisu M, Ruhi Ozyurek A, Dorak C, et al. Ballard and new ballard scoring systems in the assessment of gestational age in preterm infants. Cocuk Sagligi ve Hastaliklari Dergisi, 2001, 44(1):56-60.
35.	Chotigeat U, Jirapapa K, Layangkool T. A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. J Med Assoc Thai, 2003, 86(Suppl 3):563-569.
36.	Salama H, Alsisi A, Al-Rifai, H, et al. A randomized controlled trial on the use of oral ibuprofen to close patent ductus arteriosus in premature infants. J Neonatal Perinatal Med, 2008, 153-158.
37.	敖楨楨, 王靜. 早產兒動脈導管未閉的臨床觀察. 現代醫院, 2012, 12(2):51-52.
38.	Overmeire B, Follens I, Hartmann S, et al. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonatal Ed, 1997, 76(3):179-184.
39.	Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med, 2000, 343(10), 674-681.
40.	Lago P, Bettiol T, Salvador Si, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus:a randomised controlled trial. Eur J Pediatr, 2002, 161(4):202-207.
41.	俞建德, 來慶和, 邵波, 等. 布洛芬口服治療新生兒呼吸窘迫綜合癥合并動脈導管未閉臨床觀察. 兒科藥學雜志, 2005, 11(5):25-26.
42.	Pen-Hua Su, Jia-Yuh Chen, Chi-Ming Su, et al. Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Pediatr Int, 2003, 45(6):665-670.
43.	方文君. 布洛芬早期干預極低出生體重早產兒動脈導管未閉的研究. 福建醫科大學, 2005.
44.	范小靜. 觀察口服布洛芬治療早產兒動脈導管未閉的療效. 求醫問藥, 2013, 11(4):286.
45.	陳芳芳, 陳艷林, 陳月華. 口服布洛芬早期干預早產兒肺動脈導管未閉的療效觀察. 心理醫生, 2012,(7):296-297.
46.	胡穎宇, 林泳, 林治. 口服布洛芬治療早產兒PDA的臨床觀察. 新余高專學報, 2009, 14(6):94.
47.	逯艷梅, 曹甦. 布洛芬混懸液治療新生兒動脈導管未閉療效觀察. 中國誤診學雜志, 2010, 10(28):6849-6849.
48.	楊傳忠, 楊曉東, 等. 口服布洛芬治療早產兒動脈導管未閉的前瞻性隨機對照研究. 中華圍產醫學雜志, 2010, 6(14):328-332.
49.	De Carolis MP, Romagnoli C, Polimeni V, et al. Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants. Eur J Pediatr, 2000, 159(5):364-368.
50.	Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev, 2011, 7:CD004213.
51.	徐春光, 肖昕, 熊愛華, 等. 布洛芬與吲哚美辛治療早產兒動脈導管未閉對照研究的Meta分析. 實用兒科臨床雜志, 2004, 19(6):489-491.
52.	楊瓊芳. 布洛芬及吲哚美辛治療嬰兒動脈導管未閉的Meta分析. 重慶醫學, 2014, 43(24):3176-3179.

1. Fanos V, Pusceddu M, Dess?` A, Marcialis MA. Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns? Clinics, 2011, 66(12):2141-2149.
2. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics, 2010, 125(5):1020-1030.
3. Sekar KC. Protective strategies to prevent patent ductus arteriosus. Chin Med J(Eng), 2010, 123(20):2914-2918.
4. Friedman WF, Hirschklau MJ, Printz MP, et al. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med, 1975, 295(10):526-529.
5. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Eng J Med, 1976, 295(10):530-533.
6. Overmeirea BV, Chemtob S. The pharmacologic closure of the patent ductus arteriosus. Seminars infetal Neonata Medicine, 2005, 10(2):177-184.
7. Itabashi K, Ohno T, Nishida H. Indomethacin responsiveness of patentnducus arteriosus and renal abnormalities in preterm infants treated with indomethacin. J Pediatr, 2003, 143(2):203-207.
8. Shaffer CL, Gal P, Ronsom JL, et al. Effect of age birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med, 2002, 30(2):343-348.
9. Hammerman C, Binnun A, Markovitch E, et al. Ductal closure with paracrtamol:A surprising new approach to patent ductus arteriosus treatment. Pediatrics, 2011, 128:e1618-e162.
10. Overmerre BV, Follens I, Hartmann S, et al. Treatment of patent ductus arteriosus with ibprofen. Arch Dis Child, 1997, 76(3):179-184.
11. 張聰聰, 程國強. 早產兒動脈導管未閉治療的進展. 中華兒科雜志, 2012, 50(11):871-873.
12. Higgins JPT, Altman DG, Sterne JAC, et al. Chapter 8:Assessing risk of bias in included studies//Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011[OL]. Available at:www.cochrane-handbook.org.
13. Gokmen T, Erdeve O, Altug N, et al. Efficacy and Safety of Oral Versus Intravenous Ibuprofen in Very Low Birth Weight Preterm Infants with Patent Ductus Arteriosus. The Gournal Of Pediatrics, 2011, 158:549-554.
14. Pistull E, Qosja A H, Shtiza D, et al. Renal effects of ibuprofen during the treatment of patent ductus arteriosus in low birth weight premature infants. Open Science Journal of Clinical Medicine, 2014, 2(6):123-128.
15. Cherif A, Khrouf N, Jabnoun S, et al. Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus. Pediatrics, 2008, 122:1256-1261.
16. Erdeve O, Yurttutan S, Altug N, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure:a randomised controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed, 2012, 97(4):279-283.
17. Jacob V. Aranda, Ronald Clyman, Blair Cox, et al. A Randomized, Double-Blind, Placebo-Controlled Trial on Intravenous Ibuprofen L-Lysine for the Early Closure of Nonsymptomatic Patent Ductus Arteriosus within 72 Hours of Birth in Extremely Low-Birth-Weight Infants. Am J Perinatol, 2009, 26(3):235-245.
18. Sangtawesin C, Sangtawesin V, Lertsutthiwong W, et al. Prophylaxis of Symptomatic Patent Ductus Arteriosuswith Oral Ibuprofen in Very Low Birth Weight Infants. J Med Assoc Thai, 2008, 91 (Suppl 3):S28-34.
19. Sangtawesin V, Sangtawesin C, Raksasinborisut C, et al. Oral Ibuprofen Prophylaxis for Symptomatic Patent Ductus Arteriosus of Prematurity. J Med Assoc Thai, 2006, 89(3):314-321.
20. 黨丹. 對乙酰氨基酚與布洛芬治療早產兒PDA的隨機對照試驗. 長春:吉林大學. 2013.
21. Oncel MY, Yurttutan S, Erdeve O, et al. Oral Paracetamol versus Oral Ibuprofen in the Management of Patent Ductus Arteriosus in Preterm Infants. J Pediatr, 2014, 164(3):510-514.
22. 龔長富, 葉慧寧, 馮立文. 口服美林對早產兒動脈導管未閉的療效觀察. 小兒急救醫學, 2004, 11(5):317-319.
23. 何莉, 王潔婷, 陸長東, 等. 口服布洛芬和消炎痛關閉早產兒動脈導管未閉的療效和安全性的比較. 中國婦幼保健, 2005, 20(6):752-754.
24. 姜紅, 吳莉華, 葛覺敏. 口服布洛芬治療早產兒動脈導管未閉的療效及安全性. 中國醫學創新, 2009, 6(23):109-110.
25. 雷立容, 丘惠嫻. 布洛芬治療極低出生體重早產兒動脈導管未閉的療效觀察. 海南醫學. 2013, 24(2):202-204.
26. 宋萃春, 張軍. 布洛芬對關閉早產兒動脈導管療效分析. 中外健康文摘, 2014, (14):167-167.
27. 楊春, 張春秀, 徐桂林. 口服布洛芬混懸劑治療早產兒動脈導管未閉的療效觀察, 2006, 22(15):1811-1812.
28. 張磊, 唐建平. 布洛芬混懸液治療新生兒動脈導管未閉的臨床療效分析. 現代診斷與治療, 2013, 24(9):2014-2015.
29. Fakhraee S H, Badiee Z, MojtahedzadehS, et al. Comparison of oral ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Zhongguo Dang Dai Er Ke Za Zhi, 2007, 9(5):399-403.
30. Hammerman C, Shchors I, Jacobson S, et al. Ibuprofen Versus Continuous Indomethacin in Premature Neonates With Patent Ductus Arteriosus:Is the Difference in the Mode of Administration? Pediatr Res, 2008, 64(3):291-298.
31. Yadav S, AgarwalS, Maria A, et al. Comparison of Oral Ibuprofen with Oral Indomethacin for PDA Closure in Indian Preterm Neonates:A Randomized Controlled Trial. Pediatr Cardiol, 2014, 35(5):824-830.
32. Aly H, Lotfy W, Badrawi N, et al. Oral Ibuprofen and Ductus Arteriosus in Premature Infants:A Randomized Pilot Study. Am J Perinatol, 2007, 24(5):267-270.
33. Adamska E, Helwich E, Rutkowska M, et al. Comparison of the efficacy of ibuprofen and indomethacin in the treatment of patent ductus arteriosus in prematurely born infants. Med Wieku Rozwoj, 2005, 9(3 Pt 1):335-354.
34. Akisu M, Ruhi Ozyurek A, Dorak C, et al. Ballard and new ballard scoring systems in the assessment of gestational age in preterm infants. Cocuk Sagligi ve Hastaliklari Dergisi, 2001, 44(1):56-60.
35. Chotigeat U, Jirapapa K, Layangkool T. A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. J Med Assoc Thai, 2003, 86(Suppl 3):563-569.
36. Salama H, Alsisi A, Al-Rifai, H, et al. A randomized controlled trial on the use of oral ibuprofen to close patent ductus arteriosus in premature infants. J Neonatal Perinatal Med, 2008, 153-158.
37. 敖楨楨, 王靜. 早產兒動脈導管未閉的臨床觀察. 現代醫院, 2012, 12(2):51-52.
38. Overmeire B, Follens I, Hartmann S, et al. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonatal Ed, 1997, 76(3):179-184.
39. Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med, 2000, 343(10), 674-681.
40. Lago P, Bettiol T, Salvador Si, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus:a randomised controlled trial. Eur J Pediatr, 2002, 161(4):202-207.
41. 俞建德, 來慶和, 邵波, 等. 布洛芬口服治療新生兒呼吸窘迫綜合癥合并動脈導管未閉臨床觀察. 兒科藥學雜志, 2005, 11(5):25-26.
42. Pen-Hua Su, Jia-Yuh Chen, Chi-Ming Su, et al. Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Pediatr Int, 2003, 45(6):665-670.
43. 方文君. 布洛芬早期干預極低出生體重早產兒動脈導管未閉的研究. 福建醫科大學, 2005.
44. 范小靜. 觀察口服布洛芬治療早產兒動脈導管未閉的療效. 求醫問藥, 2013, 11(4):286.
45. 陳芳芳, 陳艷林, 陳月華. 口服布洛芬早期干預早產兒肺動脈導管未閉的療效觀察. 心理醫生, 2012,(7):296-297.
46. 胡穎宇, 林泳, 林治. 口服布洛芬治療早產兒PDA的臨床觀察. 新余高專學報, 2009, 14(6):94.
47. 逯艷梅, 曹甦. 布洛芬混懸液治療新生兒動脈導管未閉療效觀察. 中國誤診學雜志, 2010, 10(28):6849-6849.
48. 楊傳忠, 楊曉東, 等. 口服布洛芬治療早產兒動脈導管未閉的前瞻性隨機對照研究. 中華圍產醫學雜志, 2010, 6(14):328-332.
49. De Carolis MP, Romagnoli C, Polimeni V, et al. Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants. Eur J Pediatr, 2000, 159(5):364-368.
50. Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev, 2011, 7:CD004213.
51. 徐春光, 肖昕, 熊愛華, 等. 布洛芬與吲哚美辛治療早產兒動脈導管未閉對照研究的Meta分析. 實用兒科臨床雜志, 2004, 19(6):489-491.
52. 楊瓊芳. 布洛芬及吲哚美辛治療嬰兒動脈導管未閉的Meta分析. 重慶醫學, 2014, 43(24):3176-3179.

Chinese Journal of Evidence-Based Medicine

Efficacy and Safety of Ibuprofen for Premature Infants with Patent Ductus Arteriosus: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content